<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

	<!-- RSS feed defaults -->
	<channel>
		<title>Wyss InstituteImmuno-Materials &#8211; Wyss Institute</title>
		<link>https://wyss.harvard.edu</link>
		<description>Wyss Institute at Harvard</description>
		<lastBuildDate>Thu, 16 Apr 2026 18:53:44 +0000</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
		<atom:link href="https://wyss.harvard.edu/focus-area/immuno-materials/feed/" rel="self" type="application/rss+xml" />

		<generator>https://wordpress.org/?v=6.7.1</generator>

		<!-- Start loop -->
		
			<item>
				<title>20-ish Questions with David J. Mooney</title>
				<link>https://wyss.harvard.edu/media-post/20-ish-questions-with-david-j-mooney/</link>
        <pubDate>Fri, 19 Dec 2025 13:41:58 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[David J. Mooney]]></category>
		<category><![CDATA[Harvard SEAS]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=media_post&#038;p=44490</guid>
                                                <content:encoded><![CDATA[<p>20&#x2d;ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David J. Mooney, a Founding Core Faculty member and Lead of the Immuno&#x2d;Materials platform at the Wyss Institute. He is also the Robert P. Pinkas Family Professor of Bioengineering at the Harvard John A.</p>
<p><a href="https://wyss.harvard.edu/media-post/20-ish-questions-with-david-j-mooney/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/media-post/20-ish-questions-with-david-j-mooney/</link>
          <title></title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/12/19083743/THUMBNAIL_20-ish-Questions-with-David-J-Mooney_No-Text-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=ee9a547c989fc343286407494c5071c9"/></url>
				</image>
        			</item>

		
			<item>
				<title>First-in-human clinical trial of personalized, biomaterial-based cancer vaccine demonstrates feasibility, safety, and immune activation</title>
				<link>https://wyss.harvard.edu/news/first-in-human-clinical-trial-of-personalized-biomaterial-based-cancer-vaccine-demonstrates-feasibility-safety-and-immune-activation/</link>
        <pubDate>Wed, 10 Dec 2025 17:11:46 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Research Spotlights]]></category>
		<category><![CDATA[Biomedical Engineering]]></category>
		<category><![CDATA[Cancer Vaccine]]></category>
		<category><![CDATA[Dana-Farber Cancer Institute]]></category>
		<category><![CDATA[David J. Mooney]]></category>
		<category><![CDATA[Harvard SEAS]]></category>
		<category><![CDATA[Immune System]]></category>
		<category><![CDATA[Implants]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=44432</guid>
                            <description>The successful trial provides a path to future immunotherapies, assessing advanced biomaterial-based cancer vaccines in combination with checkpoint blockade inhibitors</description>
                                        <content:encoded><![CDATA[<p>By Benjamin Boettner (BOSTON) &mdash; The first&#x2d;in&#x2d;human phase I clinical trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial&#x2d;based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with positive outcomes that encourage future vaccine developments and trials to test them in combination with immune checkpoint inhibitor&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/first-in-human-clinical-trial-of-personalized-biomaterial-based-cancer-vaccine-demonstrates-feasibility-safety-and-immune-activation/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/first-in-human-clinical-trial-of-personalized-biomaterial-based-cancer-vaccine-demonstrates-feasibility-safety-and-immune-activation/</link>
          <title>Mary Gooding, a patient who was treated with a cancer vaccine against her melanoma, in conversation with David Mooney in the Wyss Institute lab. Credit: Aram Boghosian for the <a href="https://www.bostonglobe.com/magazine/2018/08/02/boston-biotech-boom-could-bring-bold-new-treatments-for-cancer/fH7u5NLUdkA3YNTieIIzPI/story.html>Boston Globe.</a></title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/12/09105219/W4MJB5UUAII6RMDMLDEFPV2BVA.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=62c8bb0f753dd67f4511228a37ed82ba"/></url>
				</image>
        			</item>

		
			<item>
				<title>Biomaterial vaccines to make implanted orthopedic devices safer</title>
				<link>https://wyss.harvard.edu/news/biomaterial-vaccines-to-make-implanted-orthopedic-devices-safer/</link>
        <pubDate>Mon, 03 Nov 2025 19:55:42 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Antibiotic Resistance]]></category>
		<category><![CDATA[Biofilm]]></category>
		<category><![CDATA[Biomedical Engineering]]></category>
		<category><![CDATA[David J. Mooney]]></category>
		<category><![CDATA[Harvard SEAS]]></category>
		<category><![CDATA[Immune System]]></category>
		<category><![CDATA[Implants]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=42430</guid>
                            <description>Biomaterial vaccines using pathogen-specific antigens could significantly lower patients’ risk of infection from implanted medical devices</description>
                                        <content:encoded><![CDATA[<p>By Benjamin Boettner (BOSTON) &mdash; Patients with implanted medical devices like orthopedic joint replacements, pacemakers, and artificial heart valves run a small but significant risk that these devices get infected with bacterial pathogens. This starts them on a burdensome path requiring &ldquo;redo&rdquo; (revision) surgeries, prolonged antibiotic treatments, or in severe cases amputation.</p>
<p><a href="https://wyss.harvard.edu/news/biomaterial-vaccines-to-make-implanted-orthopedic-devices-safer/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/biomaterial-vaccines-to-make-implanted-orthopedic-devices-safer/</link>
          <title>A team at Harvard’s Wyss Institute and SEAS has developed a novel vaccine strategy with the potential to solve the challenge of device infection in patients. Applied to a mouse model of orthopedic device infection, the vaccines worked 100-fold more effectively than much shorter-lived conventional control vaccines. Credit: Envato Elements/chormail</title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/04/08130211/4b9ffa17-ce35-4435-855f-8c1b68be5db7-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=e8efe22d2194387a73b659b03ac0598b"/></url>
				</image>
        			</item>

		
			<item>
				<title>Charles Park named 2025 STAT Wunderkind</title>
				<link>https://wyss.harvard.edu/news/charles-park-named-2025-stat-wunderkind/</link>
        <pubDate>Fri, 17 Oct 2025 18:57:05 +0000</pubDate>
        <dc:creator><![CDATA[Seth Kroll]]></dc:creator>
        		<category><![CDATA[Awards]]></category>
		<category><![CDATA[Community]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=43995</guid>
                            <description>An annual honor celebrating the unheralded heroes of science and medicine</description>
                                        <content:encoded><![CDATA[<p>By Seth Kroll (BOSTON) &mdash; The Wyss Institute is proud to announce that Charles Park, Ph.D., a postdoctoral researcher in the Wyss&rsquo; Immuno&#x2d;Materials Platform with Wyss Core Faculty member Samir Mitagotri, Ph.D., has been named a 2025 STAT Wunderkind by STAT News. The STAT Wunderkinds are annual awards that honor early&#x2d;career scientists whose creativity and perseverance are helping to reshape&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/charles-park-named-2025-stat-wunderkind/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/charles-park-named-2025-stat-wunderkind/</link>
          <title>Charles Park named 2025 STAT Wunderkind.</title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/10/17103213/Charles-Park-STAT-Wunderkind-award-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=4eba32dafbbc65d6aa86c18124c7d60f"/></url>
				</image>
        			</item>

		
			<item>
				<title>The Wyss Institute’s 2025-2026 Validation Projects</title>
				<link>https://wyss.harvard.edu/news/the-wyss-institutes-2025-2026-validation-projects/</link>
        <pubDate>Thu, 14 Aug 2025 15:00:53 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Awards]]></category>
		<category><![CDATA[Community]]></category>
		<category><![CDATA[Research Spotlights]]></category>
		<category><![CDATA[Technology Translation]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=43463</guid>
                            <description>14 teams supported this year to advance projects with future potential for real-world impact through the Wyss’ technology innovation funnel</description>
                                        <content:encoded><![CDATA[<p>Throughout recent years, the Wyss&rsquo; Validation Project mechanism has proven to be a highly valuable instrument for selecting and kick&#x2d;starting projects with early potential for positive impact on healthcare and the environment. Reaching deep into areas with major unmet needs across the diverse Grand Challenges laid out by the Institute, the newly selected projects are driven by multi&#x2d;talented teams&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/the-wyss-institutes-2025-2026-validation-projects/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/the-wyss-institutes-2025-2026-validation-projects/</link>
          <title>Senior Scientist Kwasi Adu-Berchie (center) is leading the TIB project team with Core Faculty member David Mooney (left). The team is developing tolerance-inducing biomaterials to offer patients safer, longer-lasting treatments for conditions ranging from autoimmune disease to tissue and bone injury. Credit: Wyss Institute at Harvard University</title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/08/13101608/Dave-Mooney-Lab-Candid-Lab-Coat-07873-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=b0631ddd4c73659862b34b403e537e4f"/></url>
				</image>
        			</item>

		
			<item>
				<title>David Mooney on the Mission to Save Lives Through Cancer Research</title>
				<link>https://wyss.harvard.edu/media-post/david-mooney-on-the-mission-to-save-lives-through-cancer-research/</link>
        <pubDate>Fri, 25 Jul 2025 17:02:46 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Cancer Vaccine]]></category>
		<category><![CDATA[David J. Mooney]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=media_post&#038;p=43366</guid>
                                                <content:encoded><![CDATA[<p>David Mooney, Core Faculty member of the Wyss Institute and Robert Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, discusses training immune cells to recognize and destroy cancer mutations. While current immunotherapies create nearly miraculous cures for some patients, they only work for certain cancers and a fraction of those affected. Mooney&rsquo;&#8230;</p>
<p><a href="https://wyss.harvard.edu/media-post/david-mooney-on-the-mission-to-save-lives-through-cancer-research/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/media-post/david-mooney-on-the-mission-to-save-lives-through-cancer-research/</link>
          <title></title>
					<url>https://wyss-prod.imgix.net/app/uploads/2016/08/05170302/Dave_Mooney_headshot_1500x1000-1.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=f0910a433f1bf055e59fe9e909c64e08"/></url>
				</image>
        			</item>

		
			<item>
				<title>20-ish Questions with Samir Mitragotri</title>
				<link>https://wyss.harvard.edu/media-post/20-ish-questions-with-samir-mitragotri/</link>
        <pubDate>Thu, 08 May 2025 14:52:36 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Community]]></category>
		<category><![CDATA[Harvard SEAS]]></category>
		<category><![CDATA[Samir Mitragotri]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=media_post&#038;p=42648</guid>
                                                <content:encoded><![CDATA[<p>20&#x2d;ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Samir Mitragotri, a Core Faculty member of the Wyss Institute as well as a Professor of Bioengineering and Biologically Inspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.</p>
<p><a href="https://wyss.harvard.edu/media-post/20-ish-questions-with-samir-mitragotri/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/media-post/20-ish-questions-with-samir-mitragotri/</link>
          <title></title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/05/02153357/THUMBNAIL_20ish-Questions-with-Samir-Mitragotri_No-Text-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=6e3f888a5be72547a0ff60a121e939bc"/></url>
				</image>
        			</item>

		
			<item>
				<title>Sandy Elmehrath on Closing the Gender Health Gap by Driving Progress in Endometriosis Management and Care</title>
				<link>https://wyss.harvard.edu/news/humans-of-the-wyss-sandy-elmehrath-on-closing-the-gender-health-gap-by-driving-progress-in-endometriosis-management-and-care/</link>
        <pubDate>Tue, 25 Mar 2025 14:54:32 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Community]]></category>
		<category><![CDATA[Endometriosis]]></category>
		<category><![CDATA[Humans of the Wyss]]></category>
		<category><![CDATA[Women's Health Initiative]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=42325</guid>
                                                <content:encoded><![CDATA[<p>The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. Sandy Elmehrath is all too familiar with the consequences of the gender health gap. Her great&#x2d;aunt endured many years of pain from stomach cancer, only to be diagnosed after it was too late&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/humans-of-the-wyss-sandy-elmehrath-on-closing-the-gender-health-gap-by-driving-progress-in-endometriosis-management-and-care/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/humans-of-the-wyss-sandy-elmehrath-on-closing-the-gender-health-gap-by-driving-progress-in-endometriosis-management-and-care/</link>
          <title>Wyss Scientist Sandy Elmehrath is developing noninvasive diagnostics and personalized treatment options to revolutionize care for endometriosis patients – about 15% of women globally. Credit: Wyss Institute at Harvard University</title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/03/19144422/HoW-Sandy-Elmehrath-06760-scaled.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=f41b7995285b5464f3b548510d6d65b2"/></url>
				</image>
        			</item>

		
			<item>
				<title>Reimagining infectious disease treatment for greater health equity: Kwasi Adu-Berchie</title>
				<link>https://wyss.harvard.edu/news/reimagining-infectious-disease-treatment-for-greater-health-equity-kwasi-adu-berchie/</link>
        <pubDate>Tue, 18 Mar 2025 15:00:22 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Community]]></category>
		<category><![CDATA[Biomaterials]]></category>
		<category><![CDATA[Biomedical Engineering]]></category>
		<category><![CDATA[Immune System]]></category>
		<category><![CDATA[Malaria]]></category>
		<category><![CDATA[Reimagine the World]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=42225</guid>
                            <description>Facing a malaria infection almost annually during his childhood in Ghana, while knowing the disease is nearly eradicated in other countries, inspired Wyss Scientist Kwasi Adu-Berchie to work towards more equitable health outcomes across the world </description>
                                        <content:encoded><![CDATA[<p>By Jessica Leff Listen to Kwasi tell his story |Wyss Institute &middot; Kwasi Audu&#x2d;Berchie Reimagine the World Kwasi Adu&#x2d;Berchie, traditionally named for the day of the week he was born, came into the world on a Sunday in Koforidua, Ghana. Before he started elementary school, he moved to Kumasi in the Ashanti Region, regarded by many as the cultural capital of Ghana. His father was an&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/reimagining-infectious-disease-treatment-for-greater-health-equity-kwasi-adu-berchie/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/reimagining-infectious-disease-treatment-for-greater-health-equity-kwasi-adu-berchie/</link>
          <title></title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/02/25110357/ListingImage.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=f6219f1b757c16706448ae623dec4dc1"/></url>
				</image>
        			</item>

		
			<item>
				<title>Vision for whole eye transplant</title>
				<link>https://wyss.harvard.edu/news/vision-for-whole-eye-transplant/</link>
        <pubDate>Wed, 12 Feb 2025 15:00:27 +0000</pubDate>
        <dc:creator><![CDATA[Seth Kroll]]></dc:creator>
        		<category><![CDATA[Awards]]></category>
		<category><![CDATA[ARPA-H]]></category>
		<category><![CDATA[Biostasis]]></category>
		<category><![CDATA[David J. Mooney]]></category>
		<category><![CDATA[Eye]]></category>
		<category><![CDATA[transplant]]></category>
		<category><![CDATA[vison]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=42057</guid>
                            <description>Wyss joins Stanford-led team on ARPA-H project to develop groundbreaking eye transplant technology</description>
                                        <content:encoded><![CDATA[<p>By Seth Kroll (BOSTON) &mdash; A multidisciplinary team led by Stanford University has been awarded funding from the Advanced Research Projects Agency for Health&rsquo;s (ARPA&#x2d;H) Transplantation of Human Eye Allografts (THEA) program to advance the science and technology necessary for whole eye transplantation. The VISION project, short for Viability, Imaging, Surgical, Immunomodulation, Ocular Preservation&#8230;</p>
<p><a href="https://wyss.harvard.edu/news/vision-for-whole-eye-transplant/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.harvard.edu/news/vision-for-whole-eye-transplant/</link>
          <title>The Transplantation of Human Eye Allografts, or THEA, program intends to enable whole functional eye transplantation to restore vision for the blind and visually impaired. In addition, THEA aims to develop new technologies or therapies to preserve or regrow nerves from the eye to the brain. These regenerative solutions could help prevent degenerative blindness and are a necessary step toward successful whole eye transplantation. Credit: ARPA-H</title>
					<url>https://wyss-prod.imgix.net/app/uploads/2025/02/03222310/ARPA-H-THEA-image.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=dbf657a6b939dc0ddfa971809779b55e"/></url>
				</image>
        			</item>

			</channel>
</rss>
